Terns Pharmaceuticals Achieves Major Milestone in Stock Offering
Terns Pharmaceuticals, Inc. (NASDAQ: TERN), a clinical-stage oncology company, has reached a significant milestone by successfully concluding its recent underwritten public offering. A total of 18,687,500 shares of common stock were offered, which included an impressive 2,437,500 shares purchased as part of the underwriters' full exercise of their option to acquire additional shares. The offering price was set at $40.00 per share, amounting to gross proceeds of $747.5 million, excluding costs like underwriting commissions.
Uses of Proceeds from the Offering
Funding Future Research and Development
The net proceeds from this offering will play a crucial role in furthering Terns’ commitment to its research and clinical trials. The company emphasizes its intention to utilize these funds to support the development and manufacturing of its key product candidates, particularly TERN-701. This funding will also aid in the initial steps towards a potential commercial launch of TERN-701, among other general corporate purposes.
Regulatory Compliance and Transparency
Terns has ensured its compliance with regulatory standards by conducting the public offering under a shelf registration statement that was filed with the Securities and Exchange Commission (SEC). This statement automatically became effective upon its submission, showcasing the company’s dedication to transparency and adherence to financial regulations. Investors have access to the related prospectus filings through the SEC’s online database.
About Terns Pharmaceuticals
Innovative Approaches to Oncology
Terns Pharmaceuticals is dedicated to advancing the field of oncology through innovation. The company's lead program, TERN-701, is an allosteric BCR-ABL inhibitor designed to improve treatment options for chronic myeloid leukemia (CML). The approach aims to enhance not just efficacy, but also the overall safety and convenience for patients compared to existing therapies.
Company Vision and Future Outlook
At its core, Terns aspires to redefine conventional treatment methodologies by leveraging its proprietary technologies. By focusing on high-impact medicines, Terns is positioned to make significant contributions to cancer treatment. The ongoing clinical studies and forthcoming developments will be closely watched by investors and healthcare professionals alike as the potential for improved treatment outcomes grows.
Investor and Media Contacts
Terns Pharmaceuticals encourages stakeholders interested in more information to reach out through its official contacts. For investors, Justin Ng can be contacted via email at investors@ternspharma.com. Media inquiries can be directed to Jenna Urban at media@ternspharma.com, or through CG Life.
Frequently Asked Questions
1. What was the purpose of Terns’ public offering?
The public offering aimed to raise funds to support research, development, and potential commercial activities for key product candidates like TERN-701.
2. How much money did Terns raise from the offering?
Terns raised gross proceeds of $747.5 million from the public offering before any deductions.
3. What is TERN-701?
TERN-701 is a highly selective allosteric BCR-ABL inhibitor that targets chronic myeloid leukemia with the potential for improved treatment profiles.
4. Who managed Terns' stock offering?
Jefferies, TD Cowen, and Leerink Partners served as the lead book-running managers for the stock offering, while other financial entities acted as co-managers.
5. Where can I find more information about Terns Pharmaceuticals?
Detailed information about Terns and its offerings can be accessed through the company’s filings on the SEC website and its investor relations page.
